A randomized, open-label, blinded endpoint, multi-center, cross-over study to evaluate the effect of high and low sodium diets on reduction in mean 24-hour ambulatory blood pressure in systolic hypertensive patients treated with aliskiren (300 mg).
Phase of Trial: Phase IV
Latest Information Update: 24 Mar 2011
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 17 Jul 2008 Actual end date is now 1 Nov 2008 as reported by ClinicalTrials.gov.
- 14 Jan 2008 Status changed from recruiting to completed.
- 06 Apr 2007 New trial record.